Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Ikena Oncology's share price for the quarter that ended in Mar. 2024 was $1.42. Ikena Oncology's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 48.26 Mil. Therefore, Ikena Oncology's market cap for the quarter that ended in Mar. 2024 was $68.53 Mil.
Ikena Oncology's quarterly market cap
declined
from Sep. 2023 ($190.97 Mil) to Dec. 2023 ($95.07 Mil) and
declined
from Dec. 2023 ($95.07 Mil) to Mar. 2024 ($68.53 Mil).
Ikena Oncology's annual market cap
declined
from Dec. 2021 ($451.13 Mil) to Dec. 2022 ($96.44 Mil) and
declined
from Dec. 2022 ($96.44 Mil) to Dec. 2023 ($95.07 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Ikena Oncology's Enterprise Value for Today is $-63.15 Mil.
Ikena Oncology Market Cap Historical Data
The historical data trend for Ikena Oncology's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ikena Oncology's Market Cap
For the Biotechnology subindustry, Ikena Oncology's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ikena Oncology's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ikena Oncology's Market Cap distribution charts can be found below:
* The bar in red indicates where Ikena Oncology's Market Cap falls into.
Ikena Oncology Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Ikena Oncology's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ikena Oncology (NAS:IKNA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Ikena Oncology Market Cap Related Terms
Thank you for viewing the detailed overview of Ikena Oncology's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Ikena Oncology (Ikena Oncology) Business Description
Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. its other product candidates are IK-175 and IK-595.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IKNA has been successfully added to your 